Page 259 - Read Online

Bose et al. Hepatoma Res 2019;5:24 I http://dx.doi.org/10.20517/2394-5079.2019.10 Page 9 of 9

17. Ono M, Ohta H, Ohhira M, Sekiya C, Namiki M. Measurements of immunoreative prothrombin, des-γ-carboxy prothrombin and
vitamin K in human liver tissues: overproduction of immunoreactive prothrombin in hepatocellular carcinoma. Am J Gastroenterol
1990;85:1149-54.
18. Tsai SL, Huang GT, Yang PM, Sheu JC, Sung JL, et al. Plasma des-gamma-carboxyprothrombin in the early stages of hepatocellular
carcinoma. Hepatology 1990;11:481-8.
19. Pote N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis
and prediction of microvascular invasion. J Hepatol 2015;62:848-54.
20. Lim TS, Kim DY, Han KH, Kim HS, Shin SH, et al. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances
diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol 2016;51:344-53.
21. Han C, Gao L, Bai H, Dou X. Identification of a role for serum aldoketo reductase family 1-member B10 in early detection of
hepatocellular carcinoma. Oncology Letters 2018;16:7123-30.
22. DiStefano JK, Davis B. Diagnostic and prognostic potential of AKR1B10 in human hepatocellular carcinoma. Cancers (Basel)
2019;11:E486.
23. Conigliaro A, Costa V, Lo Dico A, Saieva L, Buccheri S, et al. CD90+ liver cancer cells modulate endothelial cell phenotype through
the release of exosomes containing H19 lncRNA. Mol Cancer 2015;14:155.
24. Wang H, Hou L, Li A, Duan Y, Gao H, et al. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed
Res Int 2014;2014:864894.
25. Qu Z, Wu J, Wu J, Ji A, Qiang G, et al. Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma
diagnosis and prognosis. Oncotarget 2017;8:80666-78.
26. Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, et al. Identification of a bona fide microRNA biomarker in serum exosomes that
predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer 2015;112:532-8.
27. Liu W, Hu J, Zhou K, Chen F, Wang Z, et al. Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma.
OncoTargets Ther 2017;10:3843-51.
28. Arbelaiz A, AzkargortaM, KrawczykM, Santos-Laso A, Lapitz A, et al. Serum extracellular vesicles contain protein biomarkers for
primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 2017;66:1125-43.
29. Wang W, Li H, Zhou Y, Jie S. Peripheral blood microvesicles are potential biomarkers for hepatocellular carcinoma. Cancer Biomark
2013;13:351-7.
30. Świtlik WZ, Bielecka-Kowalska A, Karbownik MS, Kordek R, Jabłkowski M, et al. Forms of diagnostic material as sources of miRNA
biomarkers in hepatocellular carcinoma: a preliminary study. Biomark Med 2019; doi: 10.2217/bmm-2018-0485.
31. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, et al. Characterization of HULC, a novel gene with striking up-
regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007;132:330-42.
32. Liu Y, Pan S, Liu L, Zhai X, Liu J, et al. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related
hepatocellular carcinoma in a Chinese population, PLoS One 2012;7:e35145.
33. Smaldone MC, Davies BJ. BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential
targeted therapy of cancers. Curr Opin Mol Ther 2010;12:607-16.
34. Yang L, Zhang X, Li H, Liu J. The long noncoding RNA HOTAIR activates autophagy by upregulating ATG3 and ATG7 in hepatocellular
carcinoma. Mol Biosyst 2016;12:2605-12.
35. Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of
hepatocellular carcinoma after liver transplantation. Med Oncol 2012;29:1810-6.
36. Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, et al. MicroRNA-29 can regulate expression of the long non-coding RNA gene
MEG3 in hepatocellular cancer. Oncogene 2011;30:4750-6.
37. Tu ZQ, Li RJ, Mei JZ, Li XH. Down-regulation of long non-coding RNA GAS5 is associated with the prognosis of hepatocellular
carcinoma. Int J Clin Exp Pathol 2014;7:4303-9.
38. Wang F, Ying HQ, He BS, Pan YQ, Deng QW, et al. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma
through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget 2015;6:7899-917.
39. Tsang FH, Au SL, Wei L, Fan DN, Lee JM, et al. Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma
and is targeted by tumour suppressive miR-125b. Liver Int 2015;35:1597-606.
40. Zhuang LK, Yang YT, Ma X, Han B, Wang ZS, et al. MicroRNA-92b promotes hepatocellular carcinoma progression by targeting
Smad7 and is mediated by long non-coding RNA XIST. Cell Death Dis 2016;7:e2203.
41. Zhang C, Xia R, Zhang B, Wang H. The predictive powers of plasma trefoil factor 3 or its related micro RNAs for patients with
hepatocellular carcinoma. BMC Cancer 2018;18:1110.
42. Ezzat WM, Amr KS, Elhosary YA, Hegazy AE, Fahim HH, et al. Detection of DNA methylated microRNAs in hepatocellular carcinoma.
Gene 2019;702:153-7.
43. Xu RH, Wei W, Krawczyk M, Wang W, Luo H, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of
hepatocellular carcinoma. Nat Mater 2017;16:1155-61.
44. Kisiel JB, Dukek BA, Kanipakam RVSR, Ghoz HM et al. Hepatocellular carcinoma detection by plasma methylated DNA: discovery,
phase I pilot, and phase II clinical validation. Hepatology 2019;69:1180-92.
45. Li Y, Zhao J, Yu S, Wang Z, He X, et al. Extracellular Vesicles Long RNA Sequencing Reveals Abundant mRNA, circRNA, and
lncRNA in Human Blood as Potential Biomarkers for Cancer Diagnosis. Clin Chem 2019; doi: 10.1373/clinchem.2018.301291.